Crinetics Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
CRNX
CUSIP
22663K107
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 22663K107 since 12/18/2024, newest first.

Filer % of Class Filed
Wellington Management Group LLP 13G/A Amendment 5
6.8% 8/13/2026
Event 6/30/2026
FMR LLC 13G/A Amendment 4
1.4% 8/7/2026
Event 7/31/2026
Farallon Capital Management, L.L.C. 13G/A Amendment 2
8.5% 8/3/2026
Event 6/30/2026
Driehaus Capital Management LLC 13G/A Amendment 3 6.1% 5/15/2026
Event 3/31/2026
Wellington Management Group LLP 13G/A Amendment 4
7.8% 5/15/2026
Event 3/31/2026
Price T Rowe Associates Inc /MD/ 13G/A Amendment 1 5.1% 5/15/2026
Event 3/31/2026
Vanguard Capital Management LLC 13G 5.2% 4/29/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 5 0% 3/26/2026
Event 3/13/2026
Farallon Capital Partners, L.P. 13G/A Amendment 1
8.5% 2/5/2026
Event 12/31/2025
Wellington Management Group LLP 13G/A Amendment 3
8.9% 11/12/2025
Event 9/30/2025
Farallon Capital Partners, L.P. 13G
6.0% 9/8/2025
Event 8/29/2025
Wellington Management Group LLP 13G/A Amendment 2
6.2% 8/12/2025
Event 6/30/2025
FMR LLC 13G/A Amendment 3
15.0% 5/12/2025
Event 3/31/2025
Vanguard Group Inc 13G/A Amendment 4 10.0% 4/7/2025
Event 3/31/2025
Wellington Management Group LLP 13G/A Amendment 1
7.5% 2/10/2025
Event 12/31/2024
FMR LLC 13G/A Amendment 2
10.4% 2/7/2025
Event 1/31/2025
FMR LLC 13G/A Amendment 1
9.6% 2/7/2025
Event 12/31/2024
Vanguard Group Inc 13G/A Amendment 3 9.8% 1/30/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 276 127 M $4.73 B
2026 Q1 254 123 M $4.46 B
2025 Q4 257 112 M $5.20 B
2025 Q3 239 109 M $4.54 B
2025 Q2 232 105 M $3.01 B
2025 Q1 238 102 M $3.43 B
2024 Q4 257 99.7 M $5.10 B
2024 Q3 244 84.8 M $4.34 B
2024 Q2 248 84.5 M $3.78 B
2024 Q1 230 83.0 M $3.88 B
2023 Q4 203 72.8 M $2.59 B
2023 Q3 203 68.5 M $2.04 B
2023 Q2 144 54.1 M $974 M
2023 Q1 132 55.1 M $884 M
2022 Q4 128 56.8 M $1.04 B
2022 Q3 126 51.6 M $1.01 B
2022 Q2 113 50.6 M $945 M
2022 Q1 118 45.5 M $998 M
2021 Q4 122 49.5 M $1.41 B
2021 Q3 95 33.6 M $708 M
2021 Q2 85 36.8 M $736 M
2021 Q1 82 34.4 M $517 M
2020 Q4 87 30.5 M $430 M
2020 Q3 73 30.3 M $475 M
2020 Q2 80 31.5 M $546 M
2020 Q1 58 20.9 M $307 M
2019 Q4 60 17.7 M $443 M
2019 Q3 62 15.2 M $229 M
2019 Q2 64 18.9 M $473 M
2019 Q1 65 17.8 M $405 M
2018 Q4 52 16.9 M $506 M
2018 Q3 54 16.2 M $465 M